These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 35772417

  • 1. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
    Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-Mechlia M, Le Mestre S, Rojas-Castro D, Costagliola D, ANRS PREVENIR Study Group.
    Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
    [Abstract] [Full Text] [Related]

  • 2. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, Rojas Castro D, Raffi F, Chas J, Huleux T, Spire B, Capitant C, Cotte L, Meyer L, Molina JM, ANRS IPERGAY study group.
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L, ANRS IPERGAY Study Group.
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [Abstract] [Full Text] [Related]

  • 4. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB.
    Lancet; 2020 Jul 25; 396(10246):239-254. PubMed ID: 32711800
    [Abstract] [Full Text] [Related]

  • 5. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
    Wohl DA, Spinner CD, Flamm J, Hare CB, Doblecki-Lewis S, Ruane PJ, Molina JM, Mills A, Brinson C, Ramgopal M, Clarke A, Crofoot G, Martorell C, Carter C, Cox S, Hojilla JC, Shao Y, Das M, Kintu A, Baeten JM, Grant RM, Mounzer K, Mayer K.
    Lancet HIV; 2024 Aug 25; 11(8):e508-e521. PubMed ID: 39008999
    [Abstract] [Full Text] [Related]

  • 6. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG, PrEP Brasil Study Team.
    Lancet HIV; 2018 Mar 25; 5(3):e136-e145. PubMed ID: 29467098
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
    Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP, Anderson PL, Hendrix CW, Adeyeye A, Rooney JF, Rinehart AR, Cohen MS, McCauley M, Grinsztejn B, HPTN 083 Study Team.
    Lancet HIV; 2023 Dec 25; 10(12):e767-e778. PubMed ID: 37952550
    [Abstract] [Full Text] [Related]

  • 8. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.
    Laurent C, Dembélé Keita B, Yaya I, Le Guicher G, Sagaon-Teyssier L, Agboyibor MK, Coulibaly A, Traoré I, Malan JB, De Baetselier I, Eubanks A, Riegel L, Rojas Castro D, Fayé-Ketté H, Koné A, Diandé S, Dagnra CA, Serrano L, Diallo F, Mensah E, Dah TTE, Anoma C, Vuylsteke B, Spire B, CohMSM-PrEP Study Group.
    Lancet HIV; 2021 Jul 25; 8(7):e420-e428. PubMed ID: 34048794
    [Abstract] [Full Text] [Related]

  • 9. Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation study.
    Veloso VG, Cáceres CF, Hoagland B, Moreira RI, Vega-Ramírez H, Konda KA, Leite IC, Bautista-Arredondo S, Vinícius de Lacerda M, Valdez Madruga J, Farias A, Lima JN, Zonta R, Lauria L, Tamayo CVO, Flores HJS, Santa Cruz YMC, Aguayo RMM, Cunha M, Moreira J, Makkeda AR, Díaz S, Guanira JV, Vermandere H, Benedetti M, Ingold HL, Pimenta MC, Torres TS, Grinsztejn B, ImPrEP Study Group.
    Lancet HIV; 2023 Feb 25; 10(2):e84-e96. PubMed ID: 36565708
    [Abstract] [Full Text] [Related]

  • 10. Comparison between daily and on-demand PrEP (pre-exposure prophylaxis) regimen in covering condomless anal intercourse for men who have sex with men in Hong Kong: A randomized, controlled, open-label, crossover trial.
    Kwan TH, Lui GCY, Lam TTN, Lee KCK, Wong NS, Chan DPC, Lee SS.
    J Int AIDS Soc; 2021 Sep 25; 24(9):e25795. PubMed ID: 34473402
    [Abstract] [Full Text] [Related]

  • 11. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
    Marrazzo J, Tao L, Becker M, Leech AA, Taylor AW, Ussery F, Kiragu M, Reza-Paul S, Myers J, Bekker LG, Yang J, Carter C, de Boer M, Das M, Baeten JM, Celum C.
    JAMA; 2024 Mar 19; 331(11):930-937. PubMed ID: 38427359
    [Abstract] [Full Text] [Related]

  • 12. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
    Songtaweesin WN, Kawichai S, Phanuphak N, Cressey TR, Wongharn P, Saisaengjan C, Chinbunchorn T, Janyam S, Linjongrat D, Puthanakit T, CE-PID - TRC Adolescent Study Team.
    J Int AIDS Soc; 2020 Sep 19; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
    [Abstract] [Full Text] [Related]

  • 13. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente N, Préau M, Mora M, Rojas Castro D, Chidiac C, Chas J, Meyer L, Molina JM, Spire B, ANRS IPERGAY Study Group.
    AIDS Care; 2016 Sep 19; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [Abstract] [Full Text] [Related]

  • 14. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, Schmidt HA, Zablotska I, Price K, Whittaker B, Chant K, Cooper C, McGill S, Telfer B, Yeung B, Levitt G, Ogilvie EE, Dharan NJ, Hammoud MA, Vaccher S, Watchirs-Smith L, McNulty A, Smith DJ, Allen DM, Baker D, Bloch M, Bopage RI, Brown K, Carr A, Carmody CJ, Collins KL, Finlayson R, Foster R, Jackson EY, Lewis DA, Lusk J, O'Connor CC, Ryder N, Vlahakis E, Read P, Cooper DA, Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research group.
    Lancet HIV; 2018 Nov 19; 5(11):e629-e637. PubMed ID: 30343026
    [Abstract] [Full Text] [Related]

  • 15. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design.
    Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, Katlama C, Surgers L, Bébéar C, Dupin N, Ouattara M, Slama L, Pavie J, Duvivier C, Loze B, Goldwirt L, Gibowski S, Ollivier M, Ghosn J, Costagliola D, ANRS 174 DOXYVAC Study Group.
    Lancet Infect Dis; 2024 Oct 19; 24(10):1093-1104. PubMed ID: 38797183
    [Abstract] [Full Text] [Related]

  • 16. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
    Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, Loze B, Leplatois A, Aslan A, Moudachirou K, Delaugerre C, Rozenbaum W, Molina JM.
    AIDS; 2018 Sep 24; 32(15):2161-2169. PubMed ID: 30212403
    [Abstract] [Full Text] [Related]

  • 17. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
    Liegeon G, Antoni G, Pialoux G, Capitant C, Cotte L, Charreau I, Tremblay C, Cua E, Senneville E, Raffi F, Meyer L, Molina JM, ANRS-IPERGAY study group.
    J Int AIDS Soc; 2020 Feb 24; 23(2):e25420. PubMed ID: 32086878
    [Abstract] [Full Text] [Related]

  • 18. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
    Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, Goulart S, Torres TS, Marins LMS, Anderson PL, Luz PM, Costa Leite ID, Liu AY, Veloso VG, Grinsztejn B, PrEP Brasil Study TeamClinical Trial Number 01989611.
    J Int AIDS Soc; 2017 Apr 06; 20(1):21472. PubMed ID: 28418232
    [Abstract] [Full Text] [Related]

  • 19. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
    Goldwirt L, Bauer R, Liegeon G, Charreau I, Delaugerre C, Cotte L, Pialou G, Cua E, Laghzal A, Buschman L, Anderson PL, Mourah S, Meyer L, Molina JM, ANRS IPERGAY Study Group.
    J Antimicrob Chemother; 2021 Sep 15; 76(10):2675-2680. PubMed ID: 34278433
    [Abstract] [Full Text] [Related]

  • 20. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
    Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA.
    JAMA Intern Med; 2016 Jan 15; 176(1):75-84. PubMed ID: 26571482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.